08:00 , Nov 17, 2003 |  BC Week In Review  |  Company News

Biofrontera Pharmaceuticals Holding AG, Kiadis BV deal

Neurology company Biofrontera and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis (see BioCentury, Feb. 17). In July, however, Biofrontera...
08:00 , Nov 17, 2003 |  BioCentury  |  Strategy

Merger ups & downs

Restructuring in Germany is slowly progressing, with companies retooling, spinning out, selling assets and merging. But while one new merger was announced last week, another fell apart - illustrating how difficult it often is to...
08:00 , Nov 14, 2003 |  BC Extra  |  Company News

Biofrontera, Kiadis call off merger

Neurology play Biofrontera (Leverkusen, Germany) and chemistry company Kiadis terminated their previously proposed merger. The merger was driven by Biofrontera's interest to add chemistry and screening capacity from Kiadis ( see BioCentury, Feb. 17, 2003...
07:00 , Jul 21, 2003 |  BC Week In Review  |  Company News

Biofrontera Pharmaceuticals Holding AG, bioLeads deal

Biofrontera acquired all the assets of drug discovery company bioLeads, which became insolvent in March. Biofrontera will put the assets, including a library of two million natural compound fractions and a synthetic chemistry unit, into...
07:00 , Jul 21, 2003 |  BioCentury  |  Strategy

Biofrontera’s chemical attraction

When neurological company Biofrontera Pharmaceuticals Holding AG announced plans to merge with Kiadis B.V. , the attraction of Kiadis was its chemistry and screening technology, which Biofrontera said would help it develop compounds more rapidly....
07:00 , Jul 15, 2003 |  BC Extra  |  Company News

Biofrontera to acquire bioLeads assets

Neurological company Biofrontera (Leverkusen, Germany) acquired all the assets of drug discovery company bioLeads (Heidelberg, Germany), which became insolvent in March. Biofrontera will incorporate all of bioLeads' assets, including a library of two million natural...
07:00 , Sep 16, 2002 |  BC Week In Review  |  Company News

bioLeads, Elitra deal

The companies partnered to identify and develop anti-microbial therapeutics. The deal combines Elitra’s targets and cell-based assay and screening technology with bioLeads’s natural product libraries and chemistry capabilities. The companies will share responsibility for preclinical...
07:00 , Sep 12, 2002 |  BC Extra  |  Company News

bioLeads, Elitra anti-microbial deal

bioLeads (Heidelberg, Germany) and Elitra (San Diego, Calif.) partnered to identify and develop anti-microbial therapeutics. The deal combines Elitra's targets and cell-based assay and screening technology with bioLeads's natural product libraries and chemistry capabilities. The...
07:00 , Oct 15, 2001 |  BC Week In Review  |  Company News

Biofrontera Pharmaceuticals AG, bioLeads deal

The companies will collaborate to discover compounds for CNS diseases, initially in the areas of depression and pain, for outlicensing or joint development and marketing.. Biofrontera will identify and validate active and bioavailable compounds using...
08:00 , Dec 13, 1999 |  BC Week In Review  |  Company News

bioLeads board of directors update

BioLeads GmbH, Heidelberg, Germany   Business: Drug discovery   Appointed: Alfred Bach, CEO of BASF-Lynx AG, as chairman; Herbert-Ernst Finke, partner at Hannover Finanz Group; and Gerhard Hoefle, professor of natural product chemistry at Gesellschaft...